Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 2.9% on Wednesday . The stock traded as low as GBX 2.82 ($0.03) and last traded at GBX 2.99 ($0.04). 2,601,792 shares changed hands during trading, a decline of 87% from the average session volume of 19,580,727 shares. The stock had previously closed at GBX 3.08 ($0.04).
ImmuPharma Stock Down 8.1 %
The company has a market cap of £11.79 million, a P/E ratio of -283.20 and a beta of 1.53. The firm’s 50-day moving average price is GBX 1.65 and its 200-day moving average price is GBX 1.70.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- What to Know About Investing in Penny Stocks
- Retail Trends Spark Analyst Upgrades for DICK’s Sporting Goods
- Comparing and Trading High PE Ratio Stocks
- Teck Resources: America’s Ally in Rare Earth Elements
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Best Buy’s Dividend Is a Bargain With Double-Digit Upside
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
